Ku EJ, et al. - In inadequately controlled type 2 diabetes (T2D) patients (glycated hemoglobin [HbA1c], 7.5 – 12%) who were already taking three other types of OADs, researchers tested the efficacy and safety of empagliflozin as an add-on therapy. In this open label, prospective study, 268 T2D subjects were enrolled and divided into two groups, empagliflozin (EMPA 25 mg/day, n = 142) or insulin glargine (INS, n = 126), respectively. Compared to EMPA group, hypoglycemic adverse events were significantly higher in the INS group. The data presented in this work showed a regimen consisting of 4 different OADs, including EMPA, was effective and safe as a therapeutic strategy for treating T2D subjects for their glycemic control and improving other cardiovascular and metabolic indices.